We are delighted to share with you some of our latest news and recent activities. 

Scroll down to catch up on earlier newsletters.

Enjoy the read!

 

Q3 2019 Newsletter

  • The essence of Medasense in a one-minute clip
  • Clinicians reflect on the importance of nociception monitoring
  • New lectures examine how NOL monitoring helps guide drug titration
  • Introducing new commercial territories
  • Medasense Academy – our online education hub

 

Q2 2019 Newsletter

  • NOL talk at conferences in Europe and Latin America
  • How anaesthesiologists are utilizing NOL (video)
  • Clinical results you should know about
  • Introducing Medasense Academy
  • One of 50 best-in-class startups

 

Q1 2019 Newsletter

  • Clinical outcomes you should know about
  • Looking forward to seeing you in Germany!
  • ESA is around the corner
  • Driven by patient outcomes
  • Expanding global presence

 

Q4 2018 Newsletter

  • First clinical outcome study shows positive results in evaluating the role of the NOL® technology in guiding opioid administration during surgery for improved outcomes.
  • NOL® is now included in the new Intensive Care Unit International Guidelines.
  • An insightful editorial review, covering all the available nociception monitoring technologies, published recently in the Minerva Anestesiologica publication.

 

Q3 2018 Newsletter

  • Visit us at Anesthesiology 2018, 13-15 Oct.
  • New abstract presentations share the potential impact of NOL® on patient outcomes
  • New published studies
  • Thank you to everyone who stopped by the Medtronic booth at SFAR (our distribution partner in France) and joined the NOL® symposia & workshop
  • NOL® technology is now commercially available in Australia!

 

Q2 2018 Newsletter

  • Visit us at Euroanaesthesia 2018, 2-4 June
  • NOL® can guide the choice of opioids versus sympatholytic administration, according to latest abstract presented at NEARC
  • First NOL® Symposium in Romania
  • Thank you for visiting us at HOSPITALAR
  • NOL® is now officially a registered trademark!

 

Q1 2018 Newsletter

  • NOL™ technology is now commercially available across Europe, Israel and… Canada!
  • Watch world experts talk about the NOL™ technology and its benefits
  • Scientific publications and presentations
  • Medasense wins CEWIT 2017 Startup Contest
  • Medasense making waves in China